And the beat goes onis a refrain that kept rolling through my head after attending the symposium Tuesday hosted by the Womens Institute for a Secure Retirement (WISER) in Washington, D.C. The topic: retirement solutions for women.
No matter what Nutanix (NASDAQ:NTNX) does, it just can’t seem to win back the favor of the markets. In the aftermath of a strong beat-and-raise quarter that ended a stellar fiscal year for Nutanix, the market shrugged off the stock, keeping it flat at a bargain price of $22.
Despite the market’s bored reaction to the stock, opinions of it are anything but. Like many of its....More>>>
Late Tuesday, Gilead Sciences (GILD) won a court ruling in its battle with Merck (MRK) over the intellectual property rights behind its blockbuster hepatitis-C drugs Harvoni and Sovaldi. Gabelli’s Jing He stands by her contention that Gilead is “the most undervalued stock” in biotech:
Gilead Sciences CEO John Milligan Victor J. Blue/Bloomberg News
Boston, MA, based Investment company Adage Capital Partners Gp Llc buys Wells Fargo, General Dynamics, Puma Biotechnology, Johnson Controls International PLC, NextEra Energy, Walt Disney Co, The Mosaic Co, PerkinElmer, Goldman Sachs Group, NXP Semiconductors NV, sells Puma Biotechnology, LinkedIn, Sempra Energy, Allergan PLC, Honeywell International during the 3-months ended 2016-12-31, according....More>>>
The Republican win is an unexpected event that will ironically add to an already long list of headwinds Valeant Pharmaceuticals (NYSE:VRX) faces. Markets are now pricing in interest rate risks in the entire biotechnology sector. As interest on debt costs go up, biotech stocks in the early innings of drug development will have less money available for funding their clinical studies. Markets reacted....More>>>
The Under Armour stock ticker is changing, and shares of Under Armour Inc. (NYSE: UA) jumped following the news.
The company announced on Monday that it will change its Class A and Class C stock tickers. At the start of trading on Dec. 7, Under Armour Class A shares will change from “UA” to “UAA.” Also on that day, the company’s Class C common stock will....More>>>
May 12, 2017: Markets opened mixed Friday following lackluster earnings results from two more retailers, Penney’s and Nordstrom. Investors are also concerned that the turmoil in the Trump administration will delay the President’s promised tax cut package. Utilities and tech stocks traded higher while industrials provided the biggest drag. WTI crude oil for June delivery settled at $47.84....More>>>
ImmunoGen (NASDAQ:IMGN) is a clinical stage biotech company that is focused on cancer therapeutics. It has developed an antibody-drug conjugate or “ADC” technology which is already being used in an approved and marketed product and is also being developed for use in a few other clinical stage candidates that are part of ImmunoGen’s current pipeline. The lead pipeline candidate....More>>>
Stocks edged higher today despite Donald Trump trashing the health care sector in his press conference today.
The S&P 500 rose 0.3% to 2,275.32 today, while the Dow Jones Industrial Average gained 98.75 points, or 0.5%, to 19,954.28. The Nasdaq Composite advanced 0.2% to5,563.65–and hit its fifth consecutive high–despite the fact that biotech stocks tumbled....More>>>
Related MRK Agenus Shares Spike Higher Following Mid-Day Upgrade To Buy From Maxim The Stocks That Moved The S&P, Dow And Nasdaq Today The Vetr community has upgraded $MRK to 3.5-Stars. (Vetr) Related ONVO Add 3D Printing To Your Portfolio With These Stocks Organovo Holdings Sees FY 2016....More>>>
Biotech stocks have been particularly unloved during the past year, with the iShares Nasdaq Biotech Index ETF (IBB) gaining just 7% to the S&P 500′s 20% rise. Today, however, Amgen (AMGN) is getting a lot of love from the market after releasing Street beating earnings and reporting that its anti-cholesterol drug reduced heart attacks.
On Friday, small cap biotechArrowhead Pharmaceuticals (NASDAQ: ARWR) jumped 18.28% after hosting an investor & analyst R&D day to introduce its proprietary Targeted RNAi Molecule (TRiMTM) platform and to review its pipeline of RNAi therapeutic candidates. Arrowhead Pharmaceuticals develop